Vergara, Maxcryl Klenmae M.

HRN: 21-91-25  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/19/2022
CO-AMOXICLAV 625MG (TAB)
10/19/2022
10/26/2022
ORAL
625mg/tab
BID
S/P 2° RMLE With Episiotomy & Episiorrhaphy
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Skin & Soft TissueReproductive Tract    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: